Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Mersana Therapeutics (NASDAQ:MRSN) has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The company's Compensation Committee approved a restricted stock unit (RSU) award for one new employee who joined in January 2025. The grant consists of RSUs to acquire 20,610 shares of common stock.
The RSU award will vest in equal annual installments over four years, beginning February 15, 2025, contingent upon the employee's continued service with Mersana. The grant is subject to Mersana's 2022 Inducement Stock Incentive Plan and the terms of an RSU agreement.
Mersana Therapeutics (NASDAQ:MRSN) ha annunciato un'assegnazione di incentivo secondo la Regola di quotazione Nasdaq 5635(c)(4). Il Comitato per la Compensazione dell'azienda ha approvato un premio in titolo azionario vincolato (RSU) per un nuovo dipendente che è entrato in azienda a gennaio 2025. L'assegnazione consiste in RSU per acquisire 20.610 azioni ordinarie.
Il premio RSU si maturerà in rate annuali uguali nel corso di quattro anni, a partire dal 15 febbraio 2025, a condizione che il dipendente continui a lavorare per Mersana. L'assegnazione è soggetta al Piano di Incentivazione per Azioni di Incentivo per Induzione 2022 di Mersana e alle condizioni di un accordo RSU.
Mersana Therapeutics (NASDAQ:MRSN) ha anunciado una concesión por incentivo bajo la Regla de Cotización 5635(c)(4) de Nasdaq. El Comité de Compensación de la empresa aprobó un premio de unidad de acción restringida (RSU) para un nuevo empleado que se unió en enero de 2025. La concesión consiste en RSUs para adquirir 20,610 acciones ordinarias.
El premio RSU se vestirá en cuotas anuales iguales durante cuatro años, comenzando el 15 de febrero de 2025, condicionado a la continuación del servicio del empleado con Mersana. La concesión está sujeta al Plan de Incentivos de Acciones por Inducción 2022 de Mersana y a los términos de un acuerdo de RSU.
Mersana Therapeutics (NASDAQ:MRSN)는 Nasdaq 상장 규칙 5635(c)(4)에 따라 유도 보상을 발표했습니다. 회사의 보상 위원회는 2025년 1월에 입사한 새로운 직원에게 제한 주식 단위(RSU) 보상을 승인했습니다. 이 보상은 20,610주의 보통주를 취득할 수 있는 RSU로 구성됩니다.
RSU 보상은 4년 동안 연간 동일한 할부로 2025년 2월 15일부터 시작되며, 직원이 Mersana와 계속 근무하는 것을 조건으로 합니다. 이 보상은 Mersana의 2022년 유도 주식 인센티브 계획과 RSU 계약의 조건에 따라야 합니다.
Mersana Therapeutics (NASDAQ:MRSN) a annoncé une attribution d'incitation selon la règle de cotation Nasdaq 5635(c)(4). Le comité de rémunération de la société a approuvé une attribution d'unités d'actions restreintes (RSU) pour un nouvel employé qui a rejoint en janvier 2025. L'attribution consiste en des RSU pour acquérir 20 610 actions ordinaires.
L'attribution de RSU sera acquise en versements annuels égaux sur quatre ans, à compter du 15 février 2025, sous réserve du maintien du service de l'employé chez Mersana. L'attribution est soumise au plan d'incitation aux actions par induction 2022 de Mersana et aux conditions d'un accord RSU.
Mersana Therapeutics (NASDAQ:MRSN) hat eine Anreizgewährung gemäß der Nasdaq-Listing-Regel 5635(c)(4) bekannt gegeben. Der Vergabenausschuss des Unternehmens hat eine Ausschüttung von eingeschränkten Aktieneinheiten (RSU) für einen neuen Mitarbeiter genehmigt, der im Januar 2025 eingetreten ist. Die Gewährung besteht aus RSUs zur Erzielung von 20.610 Aktien des Stammkapitals.
Die RSU-Gewährung wird in gleichen jährlichen Raten über vier Jahre ab dem 15. Februar 2025 fällig, vorausgesetzt, der Mitarbeiter bleibt weiterhin bei Mersana beschäftigt. Die Gewährung unterliegt dem Anreiz-Aktienoptionsplan 2022 von Mersana und den Bedingungen eines RSU-Vertrags.
- None.
- None.
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on February 3, 2025, the Compensation Committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 20,610 shares of its common stock, to one new employee whose employment commenced in January 2025. The award was granted as an inducement material to the new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSU award will vest in equal annual installments on the first four anniversaries of February 15, 2025, subject to the employee’s continued service with Mersana on each such vesting date. The RSU award is subject to the terms and conditions of Mersana’s 2022 Inducement Stock Incentive Plan and the terms and conditions of an RSU agreement covering the grant.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
How many shares are included in Mersana Therapeutics' (MRSN) February 2025 RSU inducement grant?
What is the vesting schedule for MRSN's February 2025 inducement RSU grant?
When did Mersana Therapeutics (MRSN) approve the February 2025 inducement grant?
Under which regulatory rule was MRSN's February 2025 inducement grant issued?
